Biosimilars
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Track global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
Showing 1–12 of 17 articles
Quick answer
NovaPharmaNews Biosimilars hub for NMPA covers 17 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EirGenix Expands Japan Biosimilar Strategy at CPHI Japan 2026 Amid Regulatory Support
Biosimilars in Japan: Market Growth and PMDA Regulatory Insights 2024
Biosimilar Market in Japan: Growth Trends Post-PMDA Guideline Revisions
Biosimilar Landscape Japan: PMDA Regulatory Updates & Market Access 2024
Biosimilar Regulation Japan: Aligning PMDA with EMA and FDA Guidelines
Biosimilar Landscape in Japan: Impact of PMDA Guideline Updates 2025
Samsung Bioepis Begins Phase 1 Trial for Novel ADC SBE303, Expands Sandoz Biosimilar Partnership
Biosimilar Market Growth Japan: Impact of PMDA's 2024 Regulatory Update
Mabwell Bioscience Passes First PIC/S Member GMP Inspection for Denosumab Biosimilars in Jordan
Mabwell Subsidiary T-mab Passes Jordan GMP Inspection for Denosumab Biosimilars
Biosimilar Market Growth Japan: Impact of PMDA's 2024 Interchangeability Guidelines
ICH Guidelines Biosimilar Development: Impact on APAC Approval Timelines
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.